Vext Science, Inc.
Vext Science, Inc.
Your view on VEXTF
Overview
What the company does, where it operates, and who runs it.
About Vext Science, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Eric J. Offenberger
- Headquarters
- 4152 North 39th Avenue, Phoenix, AZ, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Eric J. Offenberger
- Headquarters
- 4152 North 39th Avenue, Phoenix, AZ, US
Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. The company is involved in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles.
It also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. In addition, the company offers Vapen clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies under Vapen Kitchens brand.
The company was formerly known as Vapen MJ Ventures Corporation and changed its name to Vext Science, Inc. in November 2019. Vext Science, Inc. was incorporated in 2015 and is headquartered in Phoenix, Arizona .
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vext Science, Inc., and the rating behind it. VEXTF last traded at $0.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vext Science, Inc.. Starting points for Vext Science, Inc.: EPS -$0.06, beta 0.91 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vext Science, Inc.. Vext Science, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vext Science, Inc.. Trailing twelve-month EPS for Vext Science, Inc. stands at -$0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vext Science, Inc.. Vext Science, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vext Science, Inc. valued side by side against its closest peers. Vext Science, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vext Science, Inc., and how their positions are changing. At a $43.8M market value, institutional positions materially move Vext Science, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vext Science, Inc. executives and directors. Shares of Vext Science, Inc. have traded between $0.07 and $0.32 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vext Science, Inc.. Vext Science, Inc. is a $43.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vext Science, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vext Science, Inc.. Coverage tracks Vext Science, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.